James Gallagher1, Suzanne McCarthy, Stephen Byrne. 1. Pharmaceutical Care Research Group, School of Pharmacy, Cavanagh Pharmacy Building, University College Cork, Cork, Ireland, j.e.gallagher@umail.ucc.ie.
Abstract
BACKGROUND: Clinical and cost-effectiveness evidence are needed to justify the existence or extension of routine clinical pharmacy services in hospital settings. Previous reviews have indicated that clinical pharmacist interventions are likely to have a positive economic impact on hospital budgets but highlighted issues relating to the quality of studies. AIM OF THE REVIEW: The primary aim of this review was to feature economic evaluations of clinical pharmacy services which targeted hospital inpatients. The review focused on the current cost-effectiveness status of different services, in addition to evaluating the quality of individual studies. Results of this systematic review were compared with cost-effectiveness and quality related findings of reviews which considered earlier time frames and alternative settings. METHODS: A systematic review of the literature included a review of the following databases: Academic Search Complete, Cochrane Library, EconLit, Embase Elsevier, NHS Economic Evaluation Database and PubMed. Only studies with an economic assessment of a clinical pharmacy service provided in a hospital setting were included. Data relating to the cost-effectiveness was extracted from eligible studies. Methodologies employed and overall quality of the studies was also reviewed. A grading system was applied to determine the quality of studies. Consolidated Health Economic Evaluation Reporting Standards statement was employed to determine which aspects of a high quality health economic study were employed. RESULTS: Twenty studies were deemed eligible for inclusion. Overall, pharmacist interventions had a positive impact on hospital budgets. Only three studies (15 %) were deemed to be "good-quality" studies. No 'novel'clinical pharmacist intervention was identified during the course of this review. CONCLUSIONS: Clinical pharmacy interventions continue to provide cost savings. However, the standard of studies published has stagnated or even deteriorated in comparison with those included in previous reviews. Utilisation of published guidelines at initial stages of future studies may help improve the overall quality of studies.
BACKGROUND: Clinical and cost-effectiveness evidence are needed to justify the existence or extension of routine clinical pharmacy services in hospital settings. Previous reviews have indicated that clinical pharmacist interventions are likely to have a positive economic impact on hospital budgets but highlighted issues relating to the quality of studies. AIM OF THE REVIEW: The primary aim of this review was to feature economic evaluations of clinical pharmacy services which targeted hospital inpatients. The review focused on the current cost-effectiveness status of different services, in addition to evaluating the quality of individual studies. Results of this systematic review were compared with cost-effectiveness and quality related findings of reviews which considered earlier time frames and alternative settings. METHODS: A systematic review of the literature included a review of the following databases: Academic Search Complete, Cochrane Library, EconLit, Embase Elsevier, NHS Economic Evaluation Database and PubMed. Only studies with an economic assessment of a clinical pharmacy service provided in a hospital setting were included. Data relating to the cost-effectiveness was extracted from eligible studies. Methodologies employed and overall quality of the studies was also reviewed. A grading system was applied to determine the quality of studies. Consolidated Health Economic Evaluation Reporting Standards statement was employed to determine which aspects of a high quality health economic study were employed. RESULTS: Twenty studies were deemed eligible for inclusion. Overall, pharmacist interventions had a positive impact on hospital budgets. Only three studies (15 %) were deemed to be "good-quality" studies. No 'novel'clinical pharmacist intervention was identified during the course of this review. CONCLUSIONS: Clinical pharmacy interventions continue to provide cost savings. However, the standard of studies published has stagnated or even deteriorated in comparison with those included in previous reviews. Utilisation of published guidelines at initial stages of future studies may help improve the overall quality of studies.
Authors: Marie A Chisholm-Burns; Joshua S Graff Zivin; Jeannie Kim Lee; Christina A Spivey; Marion Slack; Richard N Herrier; Elizabeth Hall-Lipsy; Ivo Abraham; John Palmer Journal: Am J Health Syst Pharm Date: 2010-10-01 Impact factor: 2.637
Authors: Michael Pignone; Somnath Saha; Tom Hoerger; Kathleen N Lohr; Steven Teutsch; Jeanne Mandelblatt Journal: Ann Intern Med Date: 2005-06-21 Impact factor: 25.391
Authors: Don Husereau; Michael Drummond; Stavros Petrou; Chris Carswell; David Moher; Dan Greenberg; Federico Augustovski; Andrew H Briggs; Josephine Mauskopf; Elizabeth Loder Journal: Value Health Date: 2013 Mar-Apr Impact factor: 5.725
Authors: Kyle A Weant; John A Armitstead; Alim M Ladha; Deanna Sasaki-Adams; Eldad J Hadar; Matthew G Ewend Journal: Neurosurgery Date: 2009-11 Impact factor: 4.654
Authors: Lisa Dolovich; Zubin Austin; Nancy Waite; Feng Chang; Barbara Farrell; Kelly Grindrod; Sherilyn Houle; Lisa McCarthy; Lori MacCallum; Beth Sproule Journal: Can Pharm J (Ott) Date: 2018-12-25
Authors: Erinn D'hulster; Charlotte Quintens; Jeroen Luyten; Raf Bisschops; Rik Willems; Willy E Peetermans; Jan Y Verbakel Journal: Int J Clin Pharm Date: 2022-01-11
Authors: Johan Granados; Pedro Amariles; Juan Pablo Botero-Aguirre; Natalia Andrea Ortiz-Cano; Andrés-Felipe Valencia-Quintero; Andrea Salazar-Ospina Journal: Int J Clin Pharm Date: 2022-01-03
Authors: Gary L O'Brien; Denis O'Mahony; Paddy Gillespie; Mark Mulcahy; Valerie Walshe; Marie N O'Connor; David O'Sullivan; James Gallagher; Stephen Byrne Journal: Drugs Aging Date: 2018-08 Impact factor: 3.923